BAP1 is linked to an inflamed tumor microenvironment and the infiltration of cytotoxic T cells, suggesting a possible synergistic activity of the combination of immunotherapy and PARP inhibitors [88,89]. The gene discussed is BAP1; the disease is neoplasm.